Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

TaiGen Biopharmaceuticals Holdings Limited (4157) AI Stock Analysis

TW:4157

TaiGen Biopharmaceuticals Holdings Limited

(TPEx:4157)

Select Model
Rating:52Neutral
Price Target:TWD 8.00â–¼(-3.50% Downside)
Action:initiatedcoverage
Date:11/09/26

TaiGen earns a middling score. Its greatest strength is an exceptionally conservative balance sheet — near-zero debt and equity funding over 90% of assets — which gives it the staying power to absorb the earnings swings that are standard for small-cap biotech. The 2025 return to operating profitability, with ~86% gross margin and positive free cash flow, is a real improvement. Offsetting this are substantial risks: a history of alternating profits and losses, past earnings boosted by one-off items, weak 2025 cash conversion (operating cash flow just ~25% of net income), and a low 4.2% return on equity. Technicals compound the caution, with the share price below all major moving averages, negative MACD and an established downtrend. A P/E of 37.2 with no dividend leaves the valuation stretched relative to demonstrated earnings power. Evidence that the current revenue base is recurring would be needed to justify a higher score.

Positive Factors
Low financial leverageConservative financing reduces financial risk and preserves flexibility for research, regulatory work, commercialization, and partnering. A strong equity base also gives TaiGen greater capacity to manage uneven revenue cycles without relying heavily on additional borrowing.
Negative Factors
Inconsistent cash generationUneven operating cash flow makes reported profitability less dependable as a source of internally funded growth. Modest cash conversion and volatile free cash flow could constrain research, regulatory, and commercialization spending if earnings weaken again over the next several quarters.

TaiGen Biopharmaceuticals Holdings Limited (4157) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%TW:4157-12.37%SPY+14.28%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 5.77B
Dividend Yield
―
Average Volume (3M)
968.50K
Price to Earnings (P/E)
36.6
Beta (1Y)
0.54
Revenue Growth
530.40%
EPS Growth
―
Country
TW
Employees
52
Sector
General
Sector Strength
55
Industry
Biotechnology

TaiGen Biopharmaceuticals Holdings Limited Business Overview & Revenue Model

Company Description

TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a...

TaiGen Biopharmaceuticals Holdings Limited Financial Statement Overview

Summary

TaiGen combines a fortress balance sheet (score 74) — debt-to-equity of just 0.05, equity funding ~92% of assets — with a genuine 2025 inflection: revenue rose to ~NT$259m from NT$151m, operating profit swung to +NT$69m, and gross margin remains exceptional at ~86%. However, the income statement (56) and cash flow (48) reflect the volatility typical of a small-cap biotech: losses in 2020, 2022 and 2024, prior profits driven by one-off or non-operating items, and 2025 operating cash flow equal to only ~25% of reported net income. Return on equity is a modest 4.2% and equity has eroded from NT$1.25bn in 2021 to NT$1.07bn. Financially secure, but durability of the turnaround is unproven.

Income Statement

56Neutral

Balance Sheet

74Positive

Cash Flow

48Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue256.46M259.47M150.65M123.13M36.23M1.29B
Gross Profit236.06M223.83M134.52M111.69M32.49M1.28B
EBITDA121.00M86.87M-6.63M172.23M-200.37M928.34M
Net Income155.12M45.18M-38.58M136.73M-237.16M775.62M
Balance Sheet
Total Assets1.06B1.17B1.17B1.23B1.05B1.39B
Cash, Cash Equivalents and Short-Term Investments915.27M1.03B1.02B1.04B899.50M924.39M
Total Debt11.43M49.22M58.71M74.69M38.47M53.46M
Total Liabilities37.84M92.38M91.96M110.94M76.98M139.11M
Stockholders Equity1.02B1.07B1.08B1.12B970.03M1.25B
Cash Flow
Free Cash Flow-76.42M16.42M-175.78M65.00K-28.73M617.24M
Operating Cash Flow-73.58M20.93M-173.09M7.46M-21.27M629.07M
Investing Cash Flow154.95M83.37M-110.87M145.46M-84.95M-306.07M
Financing Cash Flow-98.43M-34.64M-17.40M-19.99M-15.84M-18.85M

TaiGen Biopharmaceuticals Holdings Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:4157 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:4166TW:416670OutperformTWD 5.47B22.88――――
TW:1734TW:173464NeutralTWD 6.07B16.18―3.13%2.44%-3.96%
TW:4167TW:416760NeutralTWD 6.30B6.34―4.23%-0.05%64.82%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:4157TW:415752NeutralTWD 5.78B36.61――530.40%―
TW:6785TW:678541NeutralTWD 5.11B-70.18―0.13%-57.57%-312.45%

* General Sector Average

Performance Comparison

-50%0%50%TW:4157TW:1734TW:4166TW:4167TW:6785TW:7754Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:4157 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:4157TaiGen Biopharmaceuticals Holdings Limited8.29-1.23-12.92%
TW:1734Sinphar Pharmaceutical Co. Ltd.30.151.766.19%
TW:4166Orient Pharma Co., Ltd.22.55-2.05-8.33%
TW:4167Savior Lifetec Corp.19.252.4814.77%
TW:6785Alar Pharmaceuticals Inc80.10-174.64-68.56%
TW:7754Annji Pharmaceutical Co., Ltd.69.4024.7555.45%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026